Novo Nordisk Joins NLRP3 Bandwagon, Bets $70M On Ventus’ Lead Drug Candidate
Biotechnology startup Ventus Therapeutics is licensing its lead research program, a drug candidate for inflammatory disorders, to Novo Nordisk A/S (NYSE:NVO) for…
Carl Icahn Likes These 2 High Yielders: 2 Energy Suppliers That May Get ‘The Lift’
When Carl Icahn buys shares of stock, it's what is known as the “Icahn lift." This refers to the impact that the so-called "corporate raider" has on purchasing shares of an underlying company.
Biohaven’s ALS Drug Fails To Meet Study Endpoint, Second Therapy To Fail Trials In Recent Months
Biohaven Pharmaceutical Holding Company Ltd (NASDAQ: BHVN) announced results from a focused analysis of verdiperstat in the HEALEY ALS Platform Trial in amyotrophic lateral sclerosis (ALS).
Regeneron-Sanofi’s Flagship Dupixent Becomes First FDA-Approved Treatment For Prurigo Nodularis
The FDA approved Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Sanofi SA’s (NASDAQ:SNY) Dupixent (dupilumab) for the treatment of adult patients with prurigo nodularis. With…
Gilead’s Investigation Reveals Two Kingpins Directly Associated With Fake HIV Medications Scheme
U.S. District Judge Ann Donnelly has ordered to freeze several assets related to people and entities accused of operating a U.S. supply chain that distributes counterfeit bottles of Gilead Sciences Inc's (NASDAQ: GILD) HIV drugs.
Amazon Unveils First Of Its Kind Bedside Sleep Tracker: Checkout Features
Amazon.com Inc (NASDAQ:AMZN) announced a contactless gadget that can monitor people’s sleep. The online retailer said its $139.99 sleep gadget, dubbed…
MaxCyte Inks Platform License With Vertex For Gene-Editing Program For Rare Blood Disorders
MaxCyte Inc (NASDAQ: MXCT) has signed a
He Bet Against Subprime Mortgages, Now John Paulson Is Bullish On Gold Stocks: 2 Gold Mining High Yielders He Owns
A Wall Street investor, who's his claim to fame was betting against subprime mortgages by using credit default swaps, appears to be bullish on equities in the gold sector.
Europe’s Health Agency Accepts Moderna’s Filing For Its Updated Omicron-Targeted COVID-19 Vaccine
The European Medicines Agency (EMA) has accepted a variation for evaluating Moderna Inc’s (NASDAQ:MRNA) 50 µg booster dose of the Omicron-containing…
